Harpoon Therapeutics, Inc. Common Stock
HARP
HARP was delisted on the 8th of March, 2024.
46 hedge funds and large institutions have $12.9M invested in Harpoon Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 12 closing their positions.
3,030% more call options, than puts
Call options by funds: $313K | Put options by funds: $10K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
6% less capital invested
Capital invested by funds: $13.7M → $12.9M (-$767K)
6% less funds holding
Funds holding: 49 → 46 (-3)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$310K |
| 2 |
LPC
Lion Point Capital
New York
|
+$142K |
| 3 |
B
Bailard
Foster City,
California
|
+$53.1K |
| 4 |
Two Sigma Investments
New York
|
+$48K |
| 5 |
CWA
CM Wealth Advisors
Beachwood,
Ohio
|
+$42.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$753K |
| 2 |
Millennium Management
New York
|
-$491K |
| 3 |
LCS
Levin Capital Strategies
New York
|
-$239K |
| 4 |
BlackRock
New York
|
-$130K |
| 5 |
Renaissance Technologies
New York
|
-$115K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FIA
51
FNY Investment Advisers
New York
| – | -$1K | -200 | Closed |
|
|
BAM
52
Belpointe Asset Management
Reno,
Nevada
| – | -$1.38K | -190 | Closed |
|
53
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$241 | -33 | Closed |
|
|
NA
54
NewEdge Advisors
New Orleans,
Louisiana
| – | -$83 | -12 | Closed |
|
55
Citigroup
New York
| – | -$28 | -4 | Closed |
|
|
HFS
56
Hantz Financial Services
Southfield,
Michigan
| – | +$17 | +2 | New |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$505 | +60 | New |
|
HARP Hedge Fund Activity: Q1 2023 in Review
46 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Harpoon Therapeutics, Inc. Common Stock (HARP) for Q1 2023, worth a combined $12.9M — down 5.6% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of HARP and 10 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was Kennedy Capital Management, adding an estimated $310K. The largest seller was OrbiMed, cutting an estimated $753K.
- 46 institutional investors held Harpoon Therapeutics, Inc. Common Stock (HARP) as of Q1 2023, down from 49 in Q4 2022.
- Funds reported $12.9M of Harpoon Therapeutics, Inc. Common Stock stock for Q1 2023, down 5.6% quarter-over-quarter.
- 10 funds opened new Harpoon Therapeutics, Inc. Common Stock positions in Q1 2023 and 12 closed out, a net change of -2 holders.
- The largest Harpoon Therapeutics, Inc. Common Stock buyer in Q1 2023 was Kennedy Capital Management, an estimated $310K added.
- The largest Harpoon Therapeutics, Inc. Common Stock seller in Q1 2023 was OrbiMed, an estimated $753K sold.
Based on aggregated 13F filings for Q1 2023.